Paris - Delayed Quote EUR

Genfit S.A. (GNFT.PA)

3.4800

+0.0100

(+0.29%)

At close: December 24 at 2:00:19 PM GMT+1

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

PBC program (licensed to Ipsen): Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track with expectations; encouraging feedback from healthcare providers and payers in the U.S.UK NICE reimbursement approved and first reimbursed sales in Germany in October 2024Next €26.5M milestone payment by Ipsen pending a third pricing and reimbursement approval in Europe Scientific progress in ACLF to be featured at The Liver Meeting® 2024, with 4 posters

GlobeNewswire last month

GNFT

GNFTF
GENFIT Reports Third Quarter 2024 Financial Information

Cash and cash equivalents totaled €96.0 million as of September 30, 2024€59.7 million in revenues for the nine months ended September 30, 2024, including the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen’s Iqirvo® (elafibranor) in the U.S. for the treatment of Primary Biliary Cholangitis (PBC) Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland); November 7, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopha

GlobeNewswire last month

GNFT

GNFTF
High Growth Tech Stocks in France for October 2024

As the French CAC 40 Index experiences modest gains amid broader European optimism for potential interest rate cuts, the high-growth tech sector in France remains a focal point for investors seeking opportunities in an evolving market landscape. Identifying promising stocks often involves looking at companies with innovative technologies and strong growth potential, especially as economic conditions and policy shifts create a dynamic backdrop.

Simply Wall St. 2 months ago

VIVHY

VVVNF

GNFT
High Growth Tech Stocks in France to Watch This October 2024

As global markets experience fluctuations, with the pan-European STOXX Europe 600 Index seeing a modest rise amid potential ECB rate cuts and economic stimuli from China, France's CAC 40 Index also recorded a slight increase of 0.48%. In this dynamic environment, identifying high-growth tech stocks in France requires focusing on companies that demonstrate robust innovation capabilities and adaptability to shifting economic landscapes.

Simply Wall St. 2 months ago

OVHFF

OVHGY

BOIVF
Believe Leads These 3 High Growth Tech Stocks In France

As the pan-European STOXX Europe 600 Index shows signs of optimism with a modest rise amid hopes for quicker interest rate cuts by the European Central Bank, France's CAC 40 Index has also experienced a slight increase, reflecting a cautiously positive sentiment in the region. In this environment, identifying high-growth tech stocks requires attention to companies that demonstrate resilience and adaptability to evolving economic conditions and regulatory landscapes.

Simply Wall St. 2 months ago

BOIVF

BLV.PA

GNFT
High Growth Tech Stocks In France October 2024

As the French market navigates through a period of heightened caution due to escalating Middle East tensions and broader European economic concerns, the CAC 40 Index has experienced a notable decline. In this environment, identifying high-growth tech stocks in France requires an understanding of companies that can demonstrate resilience and adaptability amidst geopolitical uncertainties and shifting economic landscapes.

Simply Wall St. 2 months ago

INRLF

VALN

GNFT
High Growth Tech Stocks in France to Watch October 2024

As the pan-European STOXX Europe 600 Index recently ended 1.80% lower due to escalating Middle East tensions, France's CAC 40 Index also saw a decline of 3.21%, reflecting cautious investor sentiment amid geopolitical uncertainties and anticipation of an ECB rate cut due to slowing growth and inflation. In this environment, identifying high-growth tech stocks in France requires focusing on companies with strong innovation potential and resilience against macroeconomic pressures, as these...

Simply Wall St. 2 months ago

LCTSF

BLV.PA

GNFT
Exclusive Networks And 2 High Growth Tech Stocks In France

As the French market grapples with broader European economic challenges, including a decline in major indices like the CAC 40 due to escalating Middle East tensions and cautious investor sentiment, high-growth tech companies remain a focal point for potential resilience and opportunity. In this environment, identifying strong tech stocks often hinges on their ability to innovate and adapt swiftly to changing market dynamics while maintaining robust growth trajectories.

Simply Wall St. 2 months ago

INRLF

VALN

EXNWF
Esker And Two High Growth Tech Stocks In France

With the recent Fed rate cuts and a cautious but optimistic outlook for monetary policy in Europe, the market sentiment has been buoyant, particularly benefiting smaller-cap stocks. In this context, high-growth tech stocks in France present intriguing opportunities for investors seeking dynamic growth potential. When evaluating such stocks, it's crucial to consider their innovation capabilities and adaptability to evolving market conditions.

Simply Wall St. 2 months ago

ESKEF

GNFT

GNFTF
GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that the European Commission has conditionally approved Iqirvo®1 (elafibranor) 80mg tablets for the treatment of Primary Biliary Cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an ina

GlobeNewswire 3 months ago

GNFT

GNFTF
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update

Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen’s Iqirvo® (elafibranor) in the U.S. for the treatment of Primary Biliary Cholangitis (PBC)€59.0 million in revenues, including the €48.7 million milestone invoiced in June 2024 Positive opinion from the European Medicines Agency Committee in July 2024, with final decision on marketing authorization for Iqirvo anticipat

GlobeNewswire 3 months ago

GNFT

GNFTF
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) for Ipsen’s Iqirvo® (elafibranor) for the treatment of Primary Biliary Cholangitis (PBC) in

GlobeNewswire 4 months ago

GNFT

GNFTF
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) July 9, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as

GlobeNewswire 5 months ago

GNFT

GNFTF
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusion of NIS2+® as a key tool for detecting at-risk MASH1 in the European Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). The guidelines were dev

GlobeNewswire 6 months ago

GNFT

GNFTF
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis

Ipsen’s Iqirvo® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC)First-ever drug developed in-house by GENFIT to achieve U.S. FDA’s approvalGENFIT is eligible to receive a €48.7 million milestone payment from Ipsen upon the first commercial sale of Iqirvo in the U.S., as well as tiered double-digit royalties of up to 20% Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 10, 202

GlobeNewswire 6 months ago

GNFT

GNFTF
GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence at the EASL Congress™ 2024. GENFIT accelerates its research in Acute on-Chronic Liver Failure (ACLF) EF CLIF and GENFIT partnership event GENFIT will co-host an event with the European Foundation for the Study

GlobeNewswire 6 months ago

GNFT

GNFTF
GENFIT: May 22, 2024 Combined Shareholders Meeting Results

Quorum of 27.25% on first convening; allowing approval of all the resolutions Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on May 22, 2024. The quorum on first convening amounted to 27.25% and sharehol

GlobeNewswire 6 months ago

GNFT

GNFTF
GENFIT Reports First Quarter 2024 Financial Information

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of March 31, 2024 and revenues for the first three months of 2024.1 Cash position As of March 31, 2024, the Company’s cash and cash equivalents amounted to €74.0 million compared with €128.6 million as

GlobeNewswire 7 months ago

GNFT

GNFTF
GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

Lille (France), Cambridge (Massachusetts, USA), Zurich (Switzerland), April 25, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases, today announced the publication of its 2024 Extra-Financial Performance Report (fiscal year 2023). Third edition of the Extra-Financial Performance report Since 2022, GENFIT has published a detailed Extra-Financial Performance report in response to

GlobeNewswire 7 months ago

GNFT

GNFTF
GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the April 15, 2024 French legal announcements bulletin n°46 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on May 22, 2024, at 1

GlobeNewswire 8 months ago

GNFT

GNFTF

Performance Overview

Return	GNFT.PA	CAC 40
YTD	-1.69%	-3.45%
1-Year	-0.43%	-3.78%
3-Year	-25.45%	+2.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Genfit S.A. (GNFT.PA)

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

GENFIT Reports Third Quarter 2024 Financial Information

High Growth Tech Stocks in France for October 2024

High Growth Tech Stocks in France to Watch This October 2024

Believe Leads These 3 High Growth Tech Stocks In France

High Growth Tech Stocks In France October 2024

High Growth Tech Stocks in France to Watch October 2024

Exclusive Networks And 2 High Growth Tech Stocks In France

Esker And Two High Growth Tech Stocks In France

GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update

GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

GENFIT: May 22, 2024 Combined Shareholders Meeting Results

GENFIT Reports First Quarter 2024 Financial Information

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

Performance Overview